The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
 
 
Stock and Other Ownership Interests - Seattle Genetics/Astellas; UroGen pharma
Honoraria - Astellas Pharma; Bayer; Bristol-Myers Squibb; Ferring; Ipsen; Janssen; MSD; Pfizer
Consulting or Advisory Role - Astellas Pharma; Bayer; Bristol-Myers Squibb; Ferring; Ipsen; Janssen; MSD; Olympus; Pfizer; Sanofi
Speakers' Bureau - Astellas Pharma; Bayer; Bristol-Myers Squibb; Ferring; Ipsen; Janssen; MSD; Pfizer
Research Funding - Astellas Pharma (Inst); Bayer (Inst); Sanofi (Inst)
Patents, Royalties, Other Intellectual Property - Patent US07759077; Patent US20030054419; Patent US200302235816; Patent US2003235816
Travel, Accommodations, Expenses - Astellas Pharma; Janssen Oncology
Adjuvant nivolumab (NIVO) vs placebo (PBO) for high-risk muscle-invasive urothelial carcinoma (MIUC): Additional efficacy outcomes including overall survival (OS) in patients (pts) with muscle-invasive bladder cancer (MIBC) from CheckMate 274.
 
Matthew Milowsky
Stock and Other Ownership Interests - Gilead Sciences; Merck; Pfizer
Research Funding - Accuray (Inst); Acrivon Therapeutics (Inst); Alliance for Clinical Trials in Oncology (Inst); Alliance Foundation Trials (Inst); ALX Oncology (Inst); Arvinas (Inst); Astellas Pharma (Inst); Bristol-Myers Squibb (Inst); Clovis Oncology (Inst); Flare Therapeutics (Inst); G1 Therapeutics (Inst); Genentech (Inst); Hoosier Cancer Research Network (Inst); Loxo/Lilly (Inst); Merck (Inst); Mirati Therapeutics (Inst); Novartis (Inst); OncoC4 (Inst); PCCTC (Inst); Roche (Inst); Seagen (Inst)
Other Relationship - Elsevier; Medscape; Prime Education; Research to Practice
(OPTIONAL) Uncompensated Relationships - G1 Therapeutics; Loxo/Lilly
 
Matthew Galsky
Consulting or Advisory Role - Abbvie; AstraZeneca; Bicycle Therapeutics; Bristol-Myers Squibb; Curis; Daiichi Sankyo Europe GmbH; EMD Serono; Gilead Sciences; Janssen; Merck; Pfizer; Seagen
Research Funding - AstraZeneca (Inst); Bristol-Myers Squibb (Inst); Dendreon (Inst); Genentech/Roche (Inst); Janssen Oncology (Inst); Merck (Inst); Novartis (Inst)
Patents, Royalties, Other Intellectual Property - METHODS AND COMPOSITIONS FOR TREATING CANCER AND RELATED METHODS. MOUNT SINAI SCHOOL OF MEDICINE July 2012 Application number: 20120322792
 
Johannes Witjes
Consulting or Advisory Role - Astellas Pharma; Bristol-Myers Squibb; Combat Medical; Janssen Oncology; Medac; Photocure
 
Juergen Gschwend
Honoraria - Bayer Schering Pharma; Bristol-Myers Squibb; Janssen-Cilag
Consulting or Advisory Role - Bayer Schering Pharma; Bristol-Myers Squibb; Janssen-Cilag
 
Michael Schenker
Research Funding - Abbvie; Amgen; Astellas Pharma; AstraZeneca; BeiGene; BIOVEN; Bristol-Myers Squibb; Clovis Oncology; Daiichi Sankyo Europe GmbH; Eisai; Five Prime Therapeutics; Gilead Sciences; GlaxoSmithKline; Lilly; MSD; Mylan; Novartis; Pfizer/EMD Serono; PharmaMar; Regeneron; Roche; Samsung Healthcare; Sanofi/Regeneron; Tesaro
Travel, Accommodations, Expenses - Bristol Myers Squibb; Pfizer
 
Begona Perez Valderrama
Honoraria - AAA HealthCare; Almirall; Astellas Pharma; AstraZeneca Spain; Bayer; Bristol-Myers Squibb/Medarex; Janssen Oncology; Merck; MSD Oncology; Pfizer
Consulting or Advisory Role - Advanced Accelerator Applications/Novartis; Astellas Pharma; AstraZeneca; Bayer; Bristol-Meyers Squibb/Medarex; Janssen Oncology; Merck; MSD Oncology; Pfizer; Recordati
Travel, Accommodations, Expenses - Astellas Pharma; Bristol-Myers Squibb; Merck; MSD Oncology; Pfizer; Roche
 
Yoshihiko Tomita
Honoraria - Astellas Pharma; Bristol-Myers Squibb Japan; Janssen; Merck; MSD; Ono Pharmaceutical; Pfizer; Takeda
Consulting or Advisory Role - Eisai; MSD; Ono Pharmaceutical
Research Funding - Astellas Pharma (Inst); AstraZeneca (Inst); Chugai Pharma (Inst); Eisai (Inst); MSD (Inst); Ono Pharmaceutical (Inst); Pfizer (Inst); Takeda (Inst)
 
Aristotelis Bamias
Honoraria - Astellas Pharma; Bristol-Myers Squibb; Debiopharm Group; MSD; Sanofi
Consulting or Advisory Role - AstraZeneca; Bristol-Myers Squibb; Ferring; Ipsen; MSD; Pfizer; Roche
Research Funding - AstraZeneca (Inst); Bristol-Myers Squibb (Inst); Ipsen (Inst); Pfizer (Inst); Roche (Inst)
 
Thierry Lebret
Honoraria - Astellas Pharma; Bayer Schering Pharma
Consulting or Advisory Role - IPSEN; IPSEN
Travel, Accommodations, Expenses - Merck/Schering Plough; Pfizer; Pfizer
 
Shahrokh Shariat
No Relationships to Disclose
 
Se Hoon Park
Honoraria - Merck; Ono Pharmaceutical; Pfizer
Consulting or Advisory Role - Janssen Oncology
Research Funding - Merck Sharp & Dohme LLC (Inst)
 
Mads Agerbaek
No Relationships to Disclose
 
Gautam Jha
No Relationships to Disclose
 
Frank Stenner
Consulting or Advisory Role - Bristol-Myers Squibb/Roche; Ipsen; Merck; MSD; Novartis; Pfizer
Research Funding - BMS GmbH & Co. KG; Takeda
Travel, Accommodations, Expenses - BMS GmbH & Co. KG; Roche
 
Dingwei Ye
No Relationships to Disclose
 
Fabio Giudici
Employment - Bristol Myers Squibb
Stock and Other Ownership Interests - Bristol Myers Squibb
 
Jessica Connors
Employment - Bristol-Myers Squibb
Stock and Other Ownership Interests - Bristol-Myers Squibb
Travel, Accommodations, Expenses - Bristol-Myers Squibb
 
Joshua Zhang
Employment - Bristol-Myers Squibb
Stock and Other Ownership Interests - Bristol-Myers Squibb
 
Dean Bajorin
Consulting or Advisory Role - Bristol Myers Squibb Foundation; Merck
Research Funding - Astellas Pharma (Inst); AstraZeneca (Inst); Bristol-Myers Squibb (Inst); Merck (Inst); Novartis (Inst); Seattle Genetics/Astellas (Inst)